Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 68Recurrence 7Smoldering Multiple Myeloma 4Neoplasms 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Plasmablastic Lymphoma 2Lymphoma 2Leukemia, Myeloid, Acute 2Immunoglobulin Light-chain Amyloidosis 2Plasmacytoma 1Paraproteinemias 1Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Plasma Cell 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Lenalidomide 6Dexamethasone 6Cyclophosphamide 5Bortezomib 5fludarabine 3carfilzomib 3belantamab mafodotin 3pomalidomide 2fludarabine phosphate 2Melphalan 2Etoposide 2pembrolizumab 1isatuximab 1elotuzumab 1daratumumab 1Whole-Body Irradiation 1Thalidomide 1Tacrolimus 1Sirolimus 1Resistance Training 1Radiotherapy 1Pharmaceutical Preparations 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1Mycophenolic Acid 1Methotrexate 1Exercise 1Equipment and Supplies 1Doxorubicin 1Cyclosporine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × daratumumab × 90 days × Clear all
NCT03500445 2026-04-13

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

University of Chicago

Phase 2 Active not recruiting
75 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡